March 25th 2025
Pharmacists can promote prevention through the implementation of antimicrobial stewardship initiatives and advocate for fecal microbiota transplant.
Novel Molecular Imaging Agent for Detection of Bowel Inflammation in Crohn Disease Receives FDA FTD
February 10th 2025BR55, an injection of perfluorobutane/nitrogen lipopeptide-coated microbubbles, could aid in the detection of angiogenesis and allow for earlier diagnosis in patients with Crohn disease.
Read More
Updated Clinical Guidelines Outline Optimal Treatment of Helicobacter pylori Infection
For pharmacists wondering whether bismuth quadruple therapy still reigns as the gold standard, the wait is over—the latest recommendations are here.
Read More
Mitochondrial Dysfunction Present in Visceral Adipose Tissue in Patients With Obesity-Related MASH
January 29th 2025The authors note that this may cause disruptions in the metabolic stability of lipid processing and storage, impacting the liver and accelerating damaging adaptative responses.
Read More
Ustekinumab-stba Receives FDA Approval for Autoimmune Disorder and Inflammatory Bowel Disease
December 18th 2024Ustekinumab-stba (Steqeyma; Celltrion) is a subcutaneous treatment for adult and pediatric patients with plaque psoriasis arthritis, psoriatic arthritis, Crohn disease, and ulcerative colitis.
Read More
Are OTC Proton Pump Inhibitors a Boon Or a Curse?
The risk of therapy duplication with OTC and prescription PPIs can be lowered with an innovative, multi-faceted, and intentional approach by pharmacy teams and prescribers.
Read More
Heterogeneity Observed in Reporting on Drug-Drug Interactions With Proton Pump Inhibitors
July 12th 2024An analysis of interaction checkers and product summaries revealed large differences in the consistency and reliability of providing accurate information on potential drug-drug interactions.
Read More